6 research outputs found
Fluorescent ligands targeting the intracellular allosteric binding site of the chemokine receptor CCR2
Fluorescently labeled ligands are versatile molecular tools to study G protein-coupled receptors (GPCRs) and can be used for a range of different applications, including bioluminescence resonance energy transfer (BRET) assays. Here, we report the structure-based development of fluorescent ligands targeting the intracellular allosteric binding site (IABS) of the CC chemo-kine receptor 2 (CCR2), a class A GPCR that has been pursued as a drug target in oncology and inflammation. Starting from previously reported intracellular CCR2 antagonists, several tetramethylrhodamine (TAMRA) labeled CCR2 ligands were designed, synthesized and tested for their suitability as fluorescent reporters to probe binding to the IABS of CCR2. By means of these studies, we developed 14 as a fluorescent CCR2 ligand enabling cell-free as well as cellular NanoBRET-based binding studies in a non-isotopic and high-throughput manner. Further, we show that 14 can be used as a tool for fragment-based screening approaches as well. Thus, our small molecule-based fluorescent CCR2 ligand 14 represents a promising tool for future studies of CCR2 pharmacology
Discovery of 2-aminopyrimidines as potent agonists for the bitter taste receptor TAS2R14
The bitter taste receptor TAS2R14 is a G protein-coupled receptor that is found on the tongue as well as in the human airway smooth muscle and other extraoral tissues. Because its activation causes bronchodilatation, TAS2R14 is a potential target for the treatment of asthma or chronic obstructive pulmonary disease. Structural variations of flufenamic acid, a nonsteroidal anti-inflammatory drug, led us to 2-aminopyridines showing considerable efficacy and potency in an IP-One accumulation assay. In combination with a bioisosteric exchange of the carboxylic moiety by a tetrazole unit, a set of promising new TAS2R14 agonists was developed. The most potent ligand 28.1 (EC50 = 72 nM) revealed a six-fold higher potency than flufenamic acid and a maximum efficacy of 129%. Besides its unprecedented TAS2R14 activation, 28.1 revealed marked selectivity over a panel of 24 non-bitter taste human GPCRs
Development of a Fluorescent Ligand for the Intracellular Allosteric Binding Site of the Neurotensin Receptor 1
The membrane protein family of G protein-coupled receptors
(GPCRs)
represents a major class of drug targets. Over the last years, the
presence of additional intracellular binding sites besides the canonical
orthosteric binding pocket has been demonstrated for an increasing
number of GPCRs. Allosteric modulators harnessing these pockets may
represent valuable alternatives when targeting the orthosteric pocket
is not successful for drug development. Starting from SBI-553, a recently
discovered intracellular allosteric modulator for neurotensin receptor
subtype 1 (NTSR1), we developed the fluorescent molecular probe 14. Compound 14 binds to NTSR1 with an affinity
of 0.68 μM in the presence of the agonist NT(8–13). NanoBRET-based
ligand binding assays with 14 were established to derive
the affinity and structure–activity relationships for allosteric
NTSR1 modulators in a direct and nonisotopic manner, thereby facilitating
the search for and optimization of novel allosteric NTSR1 ligands.
As a consequence of cooperativity between the ligands binding to the
allosteric and orthosteric pocket, compound 14 can also
be used to investigate orthosteric NTSR1 agonists and antagonists.
Moreover, employing 14 as a probe in a drug library screening,
we identified novel chemotypes as binders for the intracellular allosteric
SBI-553 binding pocket of NTSR1 with single-digit micromolar affinity.
These hits may serve as interesting starting points for the development
of novel intracellular allosteric ligands for NTSR1 as a highly interesting
yet unexploited drug target in the fields of pain and addiction disorder
therapy
Analysis of hyperforin (St. John's wort) action at TRPC6 channel leads to the development of a new class of antidepressant drugs
St. John’s wort is an herb, long used in folk medicine for the treatment of mild depression. Its antidepressant constituent, hyperforin, has properties such as chemical instability and induction of drug-drug interactions that preclude its use for individual pharmacotherapies. Here we identify the transient receptor potential canonical 6 channel (TRPC6) as a druggable target to control anxious and depressive behavior and as a requirement for hyperforin antidepressant action. We demonstrate that TRPC6 deficiency in mice not only results in anxious and depressive behavior, but also reduces excitability of hippocampal CA1 pyramidal neurons and dentate gyrus granule cells. Using electrophysiology and targeted mutagenesis, we show that hyperforin activates the channel via a specific binding motif at TRPC6. We performed an analysis of hyperforin action to develop a new antidepressant drug that uses the same TRPC6 target mechanism for its antidepressant action. We synthesized the hyperforin analog Hyp13, which shows similar binding to TRPC6 and recapitulates TRPC6-dependent anxiolytic and antidepressant effects in mice. Hyp13 does not activate pregnan-X-receptor (PXR) and thereby loses the potential to induce drug-drug interactions. This may provide a new approach to develop better treatments for depression, since depression remains one of the most treatment-resistant mental disorders, warranting the development of effective drugs based on naturally occurring compounds
Recommended from our members
Structure-based discovery of nonopioid analgesics acting through the α2A-adrenergic receptor.
Because nonopioid analgesics are much sought after, we computationally docked more than 301 million virtual molecules against a validated pain target, the α2A-adrenergic receptor (α2AAR), seeking new α2AAR agonists chemotypes that lack the sedation conferred by known α2AAR drugs, such as dexmedetomidine. We identified 17 ligands with potencies as low as 12 nanomolar, many with partial agonism and preferential Gi and Go signaling. Experimental structures of α2AAR complexed with two of these agonists confirmed the docking predictions and templated further optimization. Several compounds, including the initial docking hit '9087 [mean effective concentration (EC50) of 52 nanomolar] and two analogs, '7075 and PS75 (EC50 4.1 and 4.8 nanomolar), exerted on-target analgesic activity in multiple in vivo pain models without sedation. These newly discovered agonists are interesting as therapeutic leads that lack the liabilities of opioids and the sedation of dexmedetomidine